Masimo Corp Stock Price, News & Analysis

Medable and Masimo have partnered to enhance clinical trials with medical-grade wearable devices. Masimo’s MightySat® Rx pulse oximeter, integrated into Medable’s platform, will be used in eight major oncology studies across 25 countries, involving over 3,000 patients. The partnership aims to improve patient participation and data quality in trials by reducing travel burdens for patients and leveraging both subjective and objective data. The collaboration is expected to yield faster enrollment and significant cost reductions in trials, with decentralized trials showing a potential ROI of $10M to $39M for Phase II and III trials.

Masimo (NASDAQ: MASI), a leader in medical technology, has been awarded the Greenhealth Approved seal by Practice Greenhealth. This recognition makes Masimo's RD pulse oximetry sensors the first in their category to meet stringent sustainability criteria. The Greenhealth seal helps healthcare providers identify environmentally preferable products effortlessly. Masimo's commitment to sustainability includes reducing waste by 84% with single-patient-use sensors, achieving zero waste to landfill through recycling, and using low-profile, lightweight components. These efforts underline Masimo's dedication to both patient care and environmental responsibility.

Masimo (NASDAQ: MASI) and Denon have launched the White PerL and PerL Pro earbuds, promising cutting-edge personalized audio. Featuring Masimo’s Adaptive Acoustic Technology (AAT), these earbuds tailor sound based on individual hearing profiles, enhancing depth, detail, and clarity. Denon's legacy of audio excellence combines with Masimo's innovation for a superior listening experience. The earbuds offer active noise cancellation, social mode, and, in the Pro model, spatial audio and adaptive noise cancellation. Available now, the Denon PerL is priced at $199, and the PerL Pro at $349.

Masimo (NASDAQ: MASI) will present at the BofA Securities Health Care Conference on May 15, 2024. A live webcast will be available on their website.

Masimo reported strong financial results for the first quarter of 2024 with consolidated revenue at $492.8 million, including healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. GAAP net income per diluted share was $0.35 and Non-GAAP net income per diluted share was $0.77. The company saw improvements in gross margins in healthcare and is increasing guidance for healthcare revenues and EPS for 2024. Masimo also announced plans to separate its consumer business.

Masimo, a global leader in monitoring technologies, received FDA clearance for Stork™, an over-the-counter baby monitoring system for infants up to 18 months. The system provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature without a prescription. It offers visual and audible alarms if readings fall outside preset ranges, utilizing advanced pulse oximetry technology. Stork is available at major retailers and online, with additional alarm features through a mobile app update. Stork features a sleek design, patented SET® sensor technology, and a camera with future AI-based features. It is FDA-cleared for OTC use, suitable for infants and neonates in home environments.